Literature DB >> 17682084

Long-term management of prolactinomas.

Janet A Schlechte1.   

Abstract

Prolactinomas are a frequent cause of gonadal dysfunction and infertility, especially in young women. The regulation of prolactin secretion and the efficacy of dopamine agonists in the therapy of prolactinomas are well established. The current challenges in management of prolactinomas are related to follow-up after successful therapy. Issues and questions to be addressed in this approach to long-term management of prolactinomas include the frequency of radiographic monitoring, effect of pregnancy and menopause, safety of estrogen in women taking oral contraceptives, and the potential for discontinuation of dopamine agonist therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17682084     DOI: 10.1210/jc.2007-0836

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  24 in total

1.  Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas.

Authors:  Sophie Vallette; Karim Serri; Juan Rivera; Patricia Santagata; Sophie Delorme; Natasha Garfield; Nora Kahtani; Hugues Beauregard; Nahla Aris-Jilwan; Ghislaine Houde; Omar Serri
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

2.  Lactation associated with a pituitary tumour in a man.

Authors:  T M Anoop; P K Jabbar; Joseph M Pappachan
Journal:  CMAJ       Date:  2010-03-01       Impact factor: 8.262

3.  Hyperprolactinemia and infertility: new insights.

Authors:  Ursula B Kaiser
Journal:  J Clin Invest       Date:  2012-10       Impact factor: 14.808

Review 4.  Prolactinoma through the female life cycle.

Authors:  Deirdre Cocks Eschler; Pedram Javanmard; Katherine Cox; Eliza B Geer
Journal:  Endocrine       Date:  2017-11-24       Impact factor: 3.633

5.  Ept7 influences estrogen action in the pituitary gland and body weight of rats.

Authors:  Scott G Kurz; Kirsten L Dennison; Nyssa Becker Samanas; Maureen Peters Hickman; Quincy A Eckert; Tiffany L Walker; Andrea S Cupp; James D Shull
Journal:  Mamm Genome       Date:  2014-01-22       Impact factor: 2.957

Review 6.  Ovarian tumor-derived ectopic hyperprolactinemia.

Authors:  Autumn F Elms; S J Carlan; Amy E Rich; Lizardo Cerezo
Journal:  Pituitary       Date:  2012-12       Impact factor: 4.107

7.  Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas.

Authors:  Beverly Mk Biller; Annamaria Colao; Stephan Petersenn; Vivien S Bonert; Marco Boscaro
Journal:  BMC Endocr Disord       Date:  2010-05-17       Impact factor: 2.763

8.  Advances in the Diagnosis, Treatment, and Molecular Genetics of Pituitary Adenomas in Childhood.

Authors:  Margaret F Keil; Constantine A Stratakis
Journal:  US Endocrinol       Date:  2009-02-01

Review 9.  Pituitary tumors in childhood: update of diagnosis, treatment and molecular genetics.

Authors:  Margaret F Keil; Constantine A Stratakis
Journal:  Expert Rev Neurother       Date:  2008-04       Impact factor: 4.618

10.  Hyperthyroidism unmasked several years after the medical and radiosurgical treatment of an invasive macroprolactinoma inducing hypopituitarism: a case report.

Authors:  Luca Foppiani; Antonio Ruelle; Paolo Cavazzani; Patrizia Del Monte
Journal:  Cases J       Date:  2009-07-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.